Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (not Kiora Pharmaceuticals) on May 27, 2021. The registrant is a Delaware corporation with its principal executive offices in Waltham, MA. The company's common stock trades on The Nasdaq Capital Market under the symbol EYEG. The filing serves as a Regulation FD disclosure to furnish an updated investor presentation to the market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to distribute an investor presentation (Exhibit 99.1) and does not contain audited financial statements or specific financial data points within the body of the text.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The primary event reported is the distribution of an updated investor presentation for use in investor communications.
Guidance, Outlook, and Risks
The filing explicitly states that the information furnished, including the attached investor presentation, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless specifically stated. The company disclaims any obligation to update the information in the future. No specific guidance, outlook, or risk factors are enumerated in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name is EyeGate Pharmaceuticals, Inc. (EYEG), not Kiora Pharmaceuticals.
- Review the attached Exhibit 99.1 (Investor Presentation) for specific financial data, as it is not included in the 8-K text.
- Confirm that the information in the presentation is not legally "filed" with the SEC and carries no obligation for future updates.
- Check the Nasdaq Capital Market for current trading status of the EYEG ticker.